Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Immune recognition of OxLDL in atherosclerosis
John F. Kearney
John F. Kearney
Published June 15, 2000
Citation Information: J Clin Invest. 2000;105(12):1683-1685. https://doi.org/10.1172/JCI10426.
View: Text | PDF
Commentary

Immune recognition of OxLDL in atherosclerosis

  • Text
  • PDF
Abstract

Authors

John F. Kearney

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Potential role of OxLDL and ApoE in autoantibody production. Top: Under ...
Potential role of OxLDL and ApoE in autoantibody production. Top: Under normal circumstances, the newly formed IgM+ B-cell population in the perinatal bone marrow or fetal liver can respond to millions of specific antigenic structures. Included in this population are anti-PC clones, some of which carry the T15 idiotype. In the selection step, PC epitopes on apoptotic material or OxLDL (selecting Ag) may enrich for T15/PC-specific B cells. The degree to which this occurs would be limited by the efficiency of debris-scavenging by macrophages or by the availability of ApoE. Additionally, these T15 clones may be stimulated to differentiate by the normally regulated amounts of PC or OxLDL (activating Ag). Bottom: In the absence of ApoE, accumulated OxLDL may promote a still more profound enrichment for T15 clones or may stimulate existing clones to differentiate into T15-producing (natural antibody–producing) plasma cells. Either possibility would give rise to the high levels of anti-OxLDL antibodies observed in the ApoE–/– mice. Circles represent B cells; ovals represent mature antibody-secreting plasma cells. Blue, αPC; yellow, T15/PC.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts